# the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

> **NCT03728543** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 62 (estimated)

## Conditions studied

- Anesthesia
- Pediatric Cancer
- Pediatric Tumor
- Pediatric Hepatoblastoma
- Beta-Thalassemia
- Hepatic Metastases

## Interventions

- **DRUG:** Sugammadex

## Key facts

- **NCT ID:** NCT03728543
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-15
- **Primary completion:** 2019-11-15
- **Final completion:** 2019-11-20
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2018-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03728543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03728543, "the Efficacy and Safety of Sugammadex in Children 0-2 Years Old". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03728543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*